Similares a Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:

20 vecinos (text_768) · 71 views · HCPLive · Estados Unidos


★	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos
3	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	88
12	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
10	Potential Biomarker to Identify Pregnant Women at Greater Risk for #Asthma Exacerbations I ATS 2026	HCPLive @hcplivenews	453	Estados Unidos	85
19	TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity	HCPLive @hcplivenews	350	Estados Unidos	84
16	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	84
20	Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3	HCPLive @hcplivenews	158	Estados Unidos	84
2	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos	88
9	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	85
15	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	84
11	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos	85
7	How to Sequence Omalizumab, Dupilumab, and Remibrutinib in CSU	HCPLive @hcplivenews	74	Estados Unidos	86
14	DUPLEX Trial Results: Key Insights in #FSGS	ReachMD @reachmd	71	Estados Unidos	84
1	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	90
13	Robert Wood, MD, on Age, Dosing in Multifood Allergy OIT	HCPLive @hcplivenews	70	Estados Unidos	84
4	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	87
5	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	87
17	Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients	HCPLive @hcplivenews	53	Estados Unidos	84
8	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	85
6	Biologic Selection in Severe Asthma: Biomarkers, Comorbidities & Switching Strategies	HCPLive @hcplivenews	36	Estados Unidos	87
18	BE HEARD EXT: Bimekizumab Shows Greater Benefit With Earlier Use in HS	HCPLive @hcplivenews	14	Estados Unidos	84